Rallybio Corp — Investor Relations & Filings
Filings indexed
246
across all filing types
Latest filing
2026-05-13
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
RLYB
Rallybio Corp. is a clinical-stage biotechnology company that develops and commercializes therapies for patients with severe and rare diseases. The company's development pipeline focuses on complement dysregulation and hematology. Key programs include RLYB116, a C5 inhibitor being investigated for complement-mediated diseases, and a therapy for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Rallybio operates with a portfolio-based model, identifying and accelerating the development of assets such as small molecules and engineered proteins to address significant unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Rallybio Corp (0001739410) (Filer) | 2026-05-13 | English | |
| 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | |
| S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | |
| 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 45759935 | 10-Q - Rallybio Corp (0001739410) (Filer) | 2026-05-13 | English | ||
| 40888387 | 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | ||
| 36271286 | S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | ||
| 32897547 | 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | ||
| 32897544 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | ||
| 32897545 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English | ||
| 32897546 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-20 | English | ||
| 31541794 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31541795 | 8-K Filing | 2026-01-29 | English | ||
| 13111487 | DEF 14A | 2026-01-02 | English | ||
|
2025
5 filings
| |||||
| 13111488 | PRE 14A | 2025-12-23 | English | ||
| 13111490 | 10-Q | 2025-11-06 | English | ||
| 13111494 | 8-K | 2025-11-06 | English | ||
| 13111491 | 8-K | 2025-08-29 | English | ||
| 13111493 | 10-Q | 2025-08-07 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Lipum AB
Clinical-stage biopharma developing novel treatments for ch…
|
LIPUM | SE | Professional, scientific and te… |
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Clinical-stage pharma company developing PP2A inhibitors to…
|
LIXT | US | Professional, scientific and te… |
|
Lunai Bioworks Inc.
Pre-clinical biotech company using AI for drug discovery an…
|
RENB | US | Professional, scientific and te… |
|
LYSOGENE
A former clinical-stage biotech that developed gene therapi…
|
LYS | FR | Professional, scientific and te… |
|
MaaT Pharma
A clinical-stage biotech developing microbiome-based therap…
|
MAAT | FR | Professional, scientific and te… |
|
Many Bright Ideas Technologies Inc.
Acquires, develops, and commercializes IP, emphasizing alte…
|
MBI.H | CA | Professional, scientific and te… |
|
MapLight Therapeutics, Inc.
Develops targeted therapies for CNS disorders using circuit…
|
MPLT | US | Professional, scientific and te… |
|
Marvel Biosciences Corp.
Developing transformative treatments for complex neurologic…
|
MRVL | CA | Professional, scientific and te… |
|
Matinas BioPharma Holdings, Inc.
Biopharma firm developing therapeutics using its Lipid Nano…
|
MTNB | US | Professional, scientific and te… |
|
Matricelf Ltd.
Develops autologous, patient-specific tissue implants for r…
|
MTLF | IL | Professional, scientific and te… |
Rallybio Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34901/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34901 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34901 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34901 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34901}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Rallybio Corp (id: 34901)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.